酷热
发表于 2025-3-23 13:14:48
Book 2016uded, as well as some ofthe ancillary .post hoc. analyses thatwere performed by variousinvestigators. The remainder of the chapter covers other solid tumormalignancies, including non-small cell lung cancer, pancreatic cancer andovarian cancer, as this treatment modality is being applied to systemicm
公式
发表于 2025-3-23 16:24:34
estigators. The remainder of the chapter covers other solid tumormalignancies, including non-small cell lung cancer, pancreatic cancer andovarian cancer, as this treatment modality is being applied to systemicm978-3-319-80840-6978-3-319-30576-9
PIZZA
发表于 2025-3-23 19:59:07
http://reply.papertrans.cn/16/1541/154023/154023_13.png
thrombosis
发表于 2025-3-23 22:52:58
http://reply.papertrans.cn/16/1541/154023/154023_14.png
dialect
发表于 2025-3-24 03:56:58
http://reply.papertrans.cn/16/1541/154023/154023_15.png
流逝
发表于 2025-3-24 10:12:31
http://reply.papertrans.cn/16/1541/154023/154023_16.png
Incorruptible
发表于 2025-3-24 12:06:18
https://doi.org/10.1007/978-3-642-91369-3e reversing and regressing in size, at a median time of 4 months. Tumor responses develop gradually and initial tumor growth may be observed even in eventual responders. Thus, we recommend that TTFields should be continued for a sufficient amount of time and that initial radiologic progression follo
歪曲道理
发表于 2025-3-24 16:43:35
https://doi.org/10.1007/978-3-642-91369-3with the device were grade 1 or 2 scalp dermatitis, and shifting of the arrays slightly during array change and applying topical corticosteroid can minimize this irritation. There were far less hematological and gastrointestinal toxicities when compared to chemotherapy. In . analyses of EF-11, secon
空洞
发表于 2025-3-24 19:55:28
http://reply.papertrans.cn/16/1541/154023/154023_19.png
天文台
发表于 2025-3-25 00:09:39
Diagnostik der Farbensinnstörungends together with maintenance temozolomide when compared to those treated with temozolomide alone. The median progression free survival was 7.1 (95 % CI 5.9–8.2) months in the TTFields plus temozolomide cohort and 4.0 (95 % CI 3.3–5.2) months in the temozolomide alone cohort (hazard ratio = 0.62 [95